Phage therapy program
Armata Pharmaceuticals
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Los Angeles, California; United States |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Clinical development program; no current general expanded-access route verified. AP-SA02 phase 3 was described as anticipated for the second half of 2026, not confirmed recruiting. |
|---|---|
| Areas of work | AP-SA02 S. aureus complicated bacteremia; AP-PA02 CF/non-CF bronchiectasis. Prior trials completed. Legacy AB-PA01/AB-SA01 expanded access no longer available. |
| International access | No public international-patient eligibility or acceptance policy verified. |
What to confirm
- Company-reported FDA designations are not approval or proof of recruiting phase 3. A pipeline is not a patient access policy.
Related studies(5)
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
Unavailable
Recorded program–study link. Website
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
Unavailable
Recorded program–study link. Website
SWARM-Pa
Completed
Recorded program–study link. Website
diSArm
Completed
Recorded program–study link. Website
Tailwind
Completed
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- AP-SA02 — Armata
- Armata Pipeline Overview
- Contact Us — Armata
- NCT05184764 — ClinicalTrials.gov
- NCT05616221 — ClinicalTrials.gov
- NCT03395743 — ClinicalTrials.gov
- NCT03395769 — ClinicalTrials.gov
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | armata |
|---|